About UCB, Inc.
At UCB, everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” We have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe diseases. We do that by connecting with patients and their families around the world living with the physical and social burdens of severe disease. Those connections offer new perspectives, drive innovation, and offer the hope of a new generation of therapies that are helping to transform lives.
With a team of approximately 7,500 employees and operations in more than 40 countries, we are a global biopharmaceutical company investing more than a quarter of our revenue in cutting-edge scientific research to meet unmet patient needs. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia. Additional U.S. UCB sites include global clinical development at our Research Triangle Park, North Carolina campus (UCB Biosciences, Inc.), and research supporting UCB’s pipeline in Cambridge, Massachusetts (UCB Research, Inc.).
244 articles with UCB, Inc.
NAYZILAM was approved to treat frequent seizure cluster episodes in epilepsy patients.
The agency approved Evenity on the basis of two Phase III clinical trials. The drug had been rejected in 2017 over safety concerns.
FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis
CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis
Patients living with non-radiographic axial spondyloarthritis, an often undiagnosed, chronic, painful and debilitating disease, now have an approved, clinically validated treatment
Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)
Results from C-AXSPAND, the first 52-week placebo-controlled study in adult patients with non-radiographic axial spondyloarthritis (nr-axSpA), demonstrated the potential impact of CIMZIA® (certolizumab pegol) when added to common background medications
Late breaking presentation of the Phase 2b long-term findings on the investigational molecule, bimekizumab, demonstrates complete or almost complete skin clearance in moderate-to-severe plaque psoriasis
UCB Full Year Report 2018: 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB's Strong Pipeline
Revenue reached € 4.6 billion: +2%, +5% CER1; net sales increased to € 4.4 billion: +5%, +8% CER, driven by core products (+6%, +10% CER)
Sanofi, UCB, McKesson Ventures, and Horizon Health Services Endorse Aetion's Vision for Real-World Evidence
This follows a 2017 rejection by the agency, requesting more data. As Jefferies analyst Michael Yee wrote in a note to clients, Amgen is “back in the game.”
Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Amgen and UCB today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics License Application (BLA) for EVENITYTM (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk for fracture at a meeting on Jan. 16, 2019.
Patient-centric drug delivery important for treatment adherence, commercial success
- Revenue reached € 3.4 billion (+3%; +6% CER)
Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients
UCB, a global biopharmaceutical company, presented long-term data for the first time from BE ACTIVE, showing that response rates across musculoskeletal and skin manifestations with bimekizumab continued to increase in the dose-blind study period after Week 12, through Week 24, and were sustained to Week 48 in psoriatic arthritis (PsA) patients.
However, because the trial did show some efficacy and met other secondary endpoints, the companies are continuing to analyze the data and decide on their next moves.
UCB Presents New Long-Term Data Showing Substantial Impact for CIMZIA® (Certolizumab Pegol) in Axial Spondyloarthritis and Rheumatoid Arthritis and Late-Breaking Bimekizumab Data in Psoriatic Arthritis
Oral presentation of results from C-AXSPAND, the first Phase 3 study to follow non-radiographic axial spondyloarthritis (nr-axSpA) patients for 52 weeks, demonstrated positive results for CIMZIA® (certolizumab pegol) in this patient population when added to common background medications
Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful improvement in multiple disease-related endpoints
On World Osteoporosis Day, Survey Finds the Impact of Fractures Due to Osteoporosis is Being Ignored
Survey finds 7 in 10 women ages 60+ think fragile bones are an inevitable part of getting older while underlying osteoporosis may be the cause
FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational produc...
8/13/2018Midazolam Nasal Spray has also been granted Fast Track designation by the US FDA due to the high unmet need for patients and caregivers
BLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 Patients
Amgen and UCB resubmitted their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Evenity (romosozumab).